Conclusion Physicians should routinely screen patients with FM for SUDs
Side effects: Note any symptoms, their severity (mild/moderate/severe), duration, and what helped
In addition, phenotyping using EHR diagnostic codes has known limitations 73 , but additional clinical data that may assist with more precise phenotyping, such as imaging, testing, and free-text notes, are currently not available in All of Us
We use these to establish a robust relationship between GLP-1R trafficking and insulin release in a manner not predicted by the standard pharmacological potency testing for cyclic adenosine monophosphate (cAMP), a primary second messenger coupling GLP-1R activation to insulin secretion 13
Most companies hold BMI thresholds to qualify patients for treatment
2019;26(3):449-61.e8